2010
DOI: 10.1007/s00436-010-1906-y
|View full text |Cite
|
Sign up to set email alerts
|

In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani

Abstract: Control of Leishmania infection relies primarily on chemotherapy, and the current drug available for treating leishmaniasis is limited. Nitazoxanide (NTZ) is a broad spectrum antiparasitic agent with activity against protozoa, nematodes, cestodes, and trematodes. In the present study, the in vitro antileishmanial efficacy of NTZ was evaluated by incubation of Leishmania donovani promastigotes with NTZ, indicating that NTZ can affect the ultrastructure of parasite promastigote and efficiently inhibit the parasi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
14
0
2

Year Published

2011
2011
2024
2024

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 24 publications
(16 citation statements)
references
References 22 publications
0
14
0
2
Order By: Relevance
“…The Leishmania isolate MHOM/CN/92/SC10H2 was originally obtained from Sichuan Province and maintained in our laboratory [22]. The parasite was grown in NNN medium at 24°C for 14 days.…”
Section: Methodsmentioning
confidence: 99%
“…The Leishmania isolate MHOM/CN/92/SC10H2 was originally obtained from Sichuan Province and maintained in our laboratory [22]. The parasite was grown in NNN medium at 24°C for 14 days.…”
Section: Methodsmentioning
confidence: 99%
“…Failure of classic chemotherapy that lies on the use of antimonial compounds as well as risks of transmission of drug resistance highlight the priority to develop novel chemotherapeutic approaches to fight the disease (Ait-Oudhia et al 2011;Santos et al 2008). Current trials which show promising results cover natural and biologically active products (Karamian et al 2007; Morais et al 2011;Moreno et al 2011;Mussi et al 2007;Shakya et al 2011;Zhang et al 2010).…”
Section: Introductionmentioning
confidence: 98%
“…For leishmaniasis, there are few new drugs in the pipeline, and the parasites resistance is increasing . In this context, the design of new delivery systems to be combined with conventional drugs aiming to reduce their toxicity (Ribeiro et al 2014a), or the use of synthetic molecules with validated antileishmanial activity being incorporated into these systems, could represent new promising strategies to obtain more effective and less toxic products (Neves et al 2010;Zhang et al 2010;Carvalho et al 2013;Ribeiro et al 2014b).…”
Section: Introductionmentioning
confidence: 98%